Valuation : EyePoint, Inc.

Market Cap 388M 334M 314M 286M 538M 36.91B 542M 3.72B 1.45B 18.72B 1.46B 1.42B 61.98B P/E 2026 *
-1.22x
P/E 2027 * -1.69x
Enterprise Value 65.16M 56.1M 52.68M 48.09M 90.34M 6.2B 90.99M 624M 243M 3.14B 245M 239M 10.41B EV / Sales 2026 *
37.9x
EV / Sales 2027 * 4.1x
Free-Float
96.47%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : EyePoint, Inc.

1 day-1.00%
1 week-10.79%
Current month-0.78%
1 month-64.05%
3 months-66.05%
6 months-75.65%
Current year-75.56%
1 week 4.35
Extreme 4.35
5.07
1 month 3.95
Extreme 3.95
14.76
Current year 3.95
Extreme 3.95
18.87
1 year 3.95
Extreme 3.95
19.11
3 years 3.91
Extreme 3.91
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
39.4
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap. Importance
20/8/26 Others

Chief Financial Officer

-139,906 0.1669%
18/8/26 Buy

Director

10,600 0.0126%
10/7/26 Exercice

Chief Executive Officer

41,393 0.0494%
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-10.79%-61.94%-57.56% 388M
+1.67%-5.09%+59.27%+110.18% 1,031B
+0.88%-1.77%+50.69%+67.20% 641B
+1.48%-2.13%+22.75%+75.53% 453B
-1.54%-7.33%+33.13%+33.51% 349B
+5.06%+1.79%+28.66%+46.21% 290B
+0.17%-4.12%+0.95%+11.79% 252B
+0.89%-2.14%+50.84%+68.59% 232B
+0.51%-4.52%-19.50%-54.83% 201B
+1.41%-0.47%+31.37%+93.17% 181B
Average +0.93%-3.44%+19.62%+39.38% 363.02B
Weighted average by Cap. +1.19%-3.97%+37.89%+66.31%

Financials

2026 *2027 *
Net sales 1.72M 1.48M 1.39M 1.27M 2.39M 164M 2.4M 16.48M 6.41M 83.01M 6.46M 6.32M 275M 17.92M 15.43M 14.49M 13.23M 24.85M 1.71B 25.02M 172M 66.8M 865M 67.29M 65.83M 2.86B
Net income -345M -297M -279M -254M -478M -32.79B -481M -3.3B -1.28B -16.63B -1.29B -1.27B -55.06B -292M -251M -236M -216M -405M -27.79B -408M -2.8B -1.09B -14.09B -1.1B -1.07B -46.66B
Net Debt -323M -278M -261M -238M -448M -30.71B -451M -3.09B -1.2B -15.57B -1.21B -1.19B -51.57B -314M -271M -254M -232M -436M -29.92B -439M -3.01B -1.17B -15.17B -1.18B -1.16B -50.24B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
02/09/26 USD 4.460 -0.89% 616,176
31/08/26 USD 4.500 +0.45% 3,506,365
28/08/26 USD 4.480 -3.24% 4,393,543
27/08/26 USD 4.630 -7.21% 5,999,646
26/08/26 USD 4.990 -0.30% 3,261,916
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
4.500USD
Average target price
27.36USD
Spread / Average Target
+508.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock